APIIC's Brian Doty says key starting materials are where domestic generic supply efforts must focus, and continuous flow chemistry makes the business case.

How the midterm results stall Trump’s MFN push, and why differential pricing, compulsory licensing and transparency dominate the WHO Fair Pricing Forum.

Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as ...

Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and ...

In the August issue of Pharmaceutical Commerce, dive into the vital role of drug wholesalers in today's complex pharma supply chain, along with content spotlighting evolving challenges patients face ...

Real-world evidence is increasingly valuable when it measurably changes clinical actions, not only when it supports publications, retrospective analyses or regulatory submissions. Information overload ...

Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient ...

Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.

Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.

In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean ...

DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years ...

Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.